– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
The FDA has approved a once-monthly injection of Eli Lilly’s Omvoh for maintenance therapy in adult patients with moderately ...
Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I have had osteoporosis for a while and recently had a bone ...
Pharmaceutical infusion center operator Infusion Express has received a $22.5 million round of growth funding and rebranded as IVX Health. The Brentwood-based company raised the capital to continue ...
Tepezza (teprotumumab-trbw) is a prescription drug that’s used to treat thyroid eye disease (TED). Tepezza comes as a powder that’s mixed with sterile water to make a liquid solution. It’s given by ...
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a ...
Effective December 21, 2023, the Centers for Medicare & Medicaid Services (CMS) has directed A/B MACs to not make downward adjustments to claims for CPT Codes for complex therapy administration (96401 ...
DEAR DR. ROACH: I have had osteoporosis for a while and recently had a bone density test that again confirmed that I have it. I am not really interested in taking an oral prescription such as Fosamax, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback